Global Testosterone Gel Market Size, Share & Trends Analysis Report, By Type (1% Solution, 1.62% Solution, 20 mg/1.25gm, 25 mg/2.5 gm, 40.5 mg/2.5gm, and 50 mg/5 gm), By Application (Primary Hypogonadism, Hypogonadotropic Hypogonadism, Late-Onset Hypogona

The global testosterone gel market is anticipated to grow at a significant CAGR during the forecast period (2022-2028). Testosterone gel is defined as a gel containing testosterone, which is delivered through the skin for treatment of low testosterone levels. It belongs to a category of drugs called androgens. These topical gels are used for the treatment of males whose bodies do not make enough natural testosterone; a condition called hypogonadism. Low levels of testosterone in men may lead to the occurrence of chronic fatigue, erectile dysfunction, decreased sexual desire, osteoporosis, and the relapse of secondary sexual features, among other conditions. Since testosterone is defined as a male hormone responsible for the development and growth of the male sex organs and maintenance of secondary sex characteristics, these gels synthetically support in the above-mentioned functions.

A full report of Global Testosterone Gel Market is available at:https://orionmarketreports.com/global-testosterone-gel-market/93917/  

Furthermore, technological advancements, changing lifestyles, and hereditary diseases may result in lower testosterone levels, which is likely to drive market expansion. Other driving factors such as liver disease, COPD, diabetes, pituitary gland disorders, and others may affect testosterone levels, and underdevelopment of the testicles, are projected to boost the demand for testosterone gel, thereby driving the global testosterone gel market growth. Some new launches of testosterone gel have been witnessed, which is also driving the market growth. For instance, in April 2019, Teva Pharmaceutical Industries Ltd. declared the launch of a generic version of AndroGel i (testosterone gel) 1.62% CIII in the US. Testosterone Gel 1.62% CIII is indicated for replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone: primary hypogonadism (congenital or acquired), and hypogonadotropic hypogonadism (congenital or acquired).

Market Coverage

The market number available for - 2021-2028
Base year- 2021
Forecast period- 2022-2028
Segment Covered- 
By Type
By Application
Regions covered-
North America
Europe
Asia-Pacific
Rest of the World
Competitive Landscape: AbbVie Inc., Teva Pharmaceutical Industries Ltd., and Lupin Ltd., among others.

Key questions addressed by the report

What is the market growth rate?
Which segment and region dominate the market in the base year?
Which segment and region will project the fastest growth in the market?
How COVID-19 impacted the market?
Deviation from the pre-COVID-19 forecast
Most affected region and segment
Who is the leader in the market?
How are players addressing challenges to sustain growth?
Where is the investment opportunity?

Global Testosterone Gel Market Report by Segment

By Type

1% Solution
62% Solution
20 mg/1.25 gm
25 mg/2.5 gm
5 mg/2.5 gm
50 mg/5 gm

By Application

Primary Hypogonadism
Hypogonadotropic Hypogonadism
Late-Onset Hypogonadism
Rest of Asia-Pacific

Media Contact:

Company Name: Orion Market Reports
Contact Person: Mr. Anurag Tiwari
Email: info@orionmarketreports.com
Contact no: +91 780-304-0404

About Us:

Orion Market Reports (OMR) endeavors to provide exclusive blend of qualitative and quantitative market research reports to clients across the globe. Our organization helps both multinational and domestic enterprises to bolster their business by providing in-depth market insights and most reliable future market trends. Our reports address all the major aspects of the markets providing insights and market outlook to global clients.

This release was published on openPR.